During the day the stock fluctuated 11.83% from a day low at $3.26 to a day high of $3.64.
…
Predicted Opening Price for CEL-SCI Corporation of Wednesday, April 13, 2022.
| Fair opening price April 13, 2022 | Current price |
|---|---|
| $3.39 | $3.29 (Undervalued) |
Similarly Why is Cel Sci stock dropping? The markets have made their biggest declines since the early uncertainty of the Covid-19 pandemic.
Will multikine get FDA approval? Multikine has not been licensed or approved by the FDA or by any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
Additionally, How does multikine work?
Multikine is designed to help the immune system “see” the tumor at a time when the immune system is still relatively intact and thereby thought to better be able to mount an attack on the tumor. The aim of treatment with Multikine is to boost the body’s immune system prior to SOC to attack the cancer.
Will Cel-Sci get FDA approval?
FDA Approval Is Highly Likely. CEL-SCI announced that the clinical trial results showing safety and efficacy with strong statistical power will form the basis of a Biologics License Application (BLA) to be filed with FDA.
What is multikine? A mixture of different immune molecules, potentially simulating the natural immune system: Multikine is composed of a defined mixture of naturally occurring molecules which in early-phase studies have been reported to be biologically/immunologically active.
What does Cel Sci do? CEL-SCI Corporation (NYSE American: CVM), a biotechnology company, is involved in the research and development of immunotherapy products for the treatment of cancer, autoimmune and infectious diseases. Use your immune system to fight disease.
What happened CEL SCI? CEL-SCI plummets 43% after phase 3 immunotherapy data misses primary endpoint. Shares of CEL-SCI Corp. (NYSE:CVM) have plummeted 43% after phase 3 data on its Multikine (leukocyte interleukin) immunotherapy candidate missed its primary endpoint for head and neck cancer.
Where is Cel Sci located?
Cel-Sci’s main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body’s immune system.
…
Cel-Sci Corporation.
| Type | Public |
|---|---|
| Headquarters | Vienna, Virginia , United States |
| Key people | Geert Kersten, CEO |
| Products | Multikine, LEAPS, HGP-30 |
| Revenue | US$559,000 (2020) |